Panitumumab
Panitumumab is a biological therapy with 167 clinical trials. Currently 34 active trials ongoing. Historical success rate of 79.1%.
Success Metrics
Based on 87 completed trials
Phase Distribution
Phase Distribution
33
Early Stage
108
Mid Stage
23
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
75.0%
87 of 116 finished
25.0%
29 ended early
34
trials recruiting
167
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Clinical Trials (167)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 167